Abstracts tagged "TH17 Cells"

Abstract Number: 0084 • ACR Convergence 2023
Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function
Jeremy Morrissette¹, Vinh Dang², Jemy Varghese², Zachary Lanzar¹, Junior Nguyen², Emily Landy³, Anastasia Frank-Kamenetskii⁴ and Scott Canna², ¹University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴CHOP/UPENN, Philadelphia, PA
Background/Purpose: Interleukin 18 (IL-18) is an inflammasome-activated cytokine that canonically amplifies interferon-gamma (IFNg) production and cytotoxicity by CD8 T-cells (CD8Ts) and Th1 CD4 T-cells (CD4Ts).…
Abstract Number: 0279 • ACR Convergence 2023
Therapeutic Exploration of Immune Checkpoint Inhibitor Induced Inflammatory Arthritis In Vivo
Sang Kim¹, Rene Rico², Naimah Turner², Trupti Trivedi², Theresa Guise² and Roza Nurieva², ¹The Univesrity of Texas MD Andesron Cancer Center, Pearland, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Despite unprecedented clinical success, immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (ICI-arthritis). Management of ICI-arthritis is challenging because…
Abstract Number: 0699 • ACR Convergence 2023
T Cell Subset Analysis in Patients with Large-Vessel Vasculitis
Rebecca Kuan¹, Christopher Redmond¹, McKella Sylvester², Mary Maclean¹, Francoise Meylan¹, Marcela Ferrada¹, Kaitlin Quinn¹ and Peter Grayson³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Colgate University, Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by granulomatous inflammation of the aorta and its major branches. The two major forms are giant cell arteritis (GCA)…
Abstract Number: 0801 • ACR Convergence 2023
LncRNA PIGL-217 Regulates Th17 Differentiation by Targeting miR-5008-5p and Suppressing FoxO1 in Behçet’s Disease
Zhimian Wang, Xin Yu, Hua Chen and Wenjie Zheng, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Dysregulated Th17 cells are implicated in Behçet's disease (BD). However, the underlying mechanism remains unclear. Here we aim to elucidate the mechanism of forkhead…
Abstract Number: 1124 • ACR Convergence 2023
A Double-blind, Placebo-parallel Controlled Phase III Clinical Study of the Efficacy and Safety of Hemay005 Tablets in Patients with Moderate to Severe Chronic Plaque Psoriasis in China
Charles Jones¹, Jianzhong Zhang², Lihua Wang³, Xunyi Dai⁴, Huimin Wang⁵, Xiadong Bi⁶, Xinsuo Duan⁷, Zudong Meng⁸, Zhongwei Tian⁹, Aie Xu¹⁰, Bin Yang¹¹, Shuping Guo¹², Wei Li¹³, Qingchun Diao¹⁴, Hong Fang¹⁵, Yongjun Liu¹⁶, Juanli Fan¹⁷, Min Yan¹⁸, Sensen Lin¹⁹, Mingfei Zhu²⁰, xianjun Hu²⁰, Jinfeng Lin²⁰ and Mingye Bi²¹, ¹Hemay Pharmaceuticals, Tianjin, China, ²Peking University People’s Hospital, Beijing, China, ³Jinan Central Hospital, Jinan, China, ⁴Wuxi Second People's Hospital, Wuxi, China, ⁵Jinzhong First People's Hospital, Jinzhong, China, ⁶Nanyang First People's Hospital, Nanyang, China, ⁷Chengde Medical College Affiliated Hospital, Chengde, China, ⁸Shiyan City People's Hospital, Shiyan, China, ⁹The First Affiliated Hospital of Xinxiang Medical College, Weihui, China, ¹⁰Hangzhou Third People's Hospital, Hangzhou, China, ¹¹Skin Disease Hospital of Southern Medical University, Guangzhou, China, ¹²The First Hospital of Shanxi Medical University, Taiyuan, China, ¹³West China Hospital of Sichuan University, Chengdu, China, ¹⁴Chongqing Traditional Chinese Medicine Hospital, Chongqing, China, ¹⁵The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ¹⁶Qiqihar Traditional Chinese Medicine Hospital, Qiqihar, China, ¹⁷Yuncheng Central Hospital, Yuncheng, China, ¹⁸Shengli Oilfield Central Hospital, Dongying, China, ¹⁹Hangzhou Tigermed, Hangzhou, China, ²⁰Clinical Department, Tianjin Hemay Pharmaceutical Co., Ltd., Tianjin, China, ²¹Wuxi People's Hospital, Wuxi, China
Background/Purpose: Hemay005 is an orally active selective PDE4 inhibitor under clinical development for treating chronic inflammatory diseases. Hemay005 significantly inhibits the activation of T lymphocytes,…
Abstract Number: 1788 • ACR Convergence 2023
The Emerging Mechanism of TNF&IL-17A/WNT5a/ROR2 Axis in Pathological Bone Formation of Ankylosing Spondylitis
Sungsin Jo¹, Seung Hoon Lee¹, Chanhyeok Jeon¹, Sung Hoon Choi², Ye-Soo Park³ and Tae-Hwan Kim⁴, ¹Hanyang University Institute for Rheumatology Research, Seoul, South Korea, ²Hanyang University Seoul Hospital, Seoul, South Korea, ³Hanyang University College of Medicine, Guri, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Enthesitis is one of the most distinctive features and signs of ectopic bone formation in ankylosing spondylitis (AS). The Wnt/β-catenin pathway and Th17 cells…
Abstract Number: 0560 • ACR Convergence 2022
IL-17 Regulates Apolipoprotein E in Lymph Node Stromal Cells During Infection and Autoimmunity
Catherine Poholek¹ and Mandy McGeachy², ¹UPM Children's Hospital of Pittsburgh/University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Autoimmune disease (AID) resulting from a dysregulated immune response is associated with substantial morbidity and mortality, largely driven by cardiovascular disease (CVD)/atherosclerosis and dyslipidemia.…
Abstract Number: 0666 • ACR Convergence 2022
HRES-1/Rab4 Controls the Overexpression of CD38 and Depletion of IL-2 in CD4+ T Cells; Potential Involvement in Proinflammatory Lineage Development in SLE
Seong Hee (Joy) Park¹, Akshay Patel² and Andras Perl³, ¹Upstate Medical University, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: HRES-1/Rab4 (Rab4A) is a small GTPase that is overexpressed in SLE patient T cells1,2, mediates the enhanced recycling of CD3 and CD4 cell surface…
Abstract Number: 1097 • ACR Convergence 2022
Intrinsic STAT1 Deficiency Underlies Proinflammatory Imprint of Naive CD4+ T Cells in Spondyloarthritis
Bilade CHERQAOUI¹, Frederic Cremazy¹, Marc Lauraine¹, Ghazal Shammas², Roula Said-Nahal³, Hendrick Mambu Mambueni⁴, Felicie Costantino², Marine Fourmont², Simon Glatigny², Luiza Maria Araujo² and Maxime Breban², ¹INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France, ²1INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France, ³Rheumatology Division - Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France, ⁴Genomic Platform of Faculty of Health Simone Veil - UVSQ university, Montigny-le-Bretonneux, France
Background/Purpose: Spondyloarthritis (SpA) development is associated with type 3 immune response activation. In HLA-B27/human β2-microglobulin transgenic rat model (B27-rat), this might at least be related…
Abstract Number: 1153 • ACR Convergence 2022
Differentially Expressed Genes in Males and Females with Ankylosing Spondylitis (AS): Transcriptomics of IL-17-producing Cells in Patients with AS
Chan Mi Lee¹, Ricky Chan², Maricela Haghiac³ and Marina Magrey⁴, ¹University Hospitals, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH, ³Metrohealth Medical Center, Cleveland, OH, ⁴Case Western Reserve University, University Hospitals, Richfield, OH
Background/Purpose: Unlike most autoimmune diseases, ankylosing spondylitis (AS) is more frequently diagnosed in men (3:1) and with a higher radiographic progression compared to women. Th17…
Abstract Number: 1157 • ACR Convergence 2022
Bacterial Indole Associated with Spondyloarthritis-Related Dysbiosis Contributes to Enhanced Th17 Immunity
Brenda Seymour¹, Brandon Trent², Brendan Allen³, Adam Berlinberg¹ and Kristi Kuhn³, ¹University of Colorado Anschutz Medical Campus, Denver, CO, ²University of Colorado Anschutz Medical Campus, Eugene, OR, ³University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: While intestinal dysbiosis and the Th17 pathway are linked to the pathophysiology of spondyloarthritis (SpA), the mechanisms by which this occurs are unknown. We…
Abstract Number: 1165 • ACR Convergence 2022
Pathogenicity of IL-17 Producing Cells in HLA-B27 Transgenic Rat Model of Spondyloarthritis
Marie Beaufrère¹, Manon Jacoutot¹, Amel Ait Ali Said¹, Roula Said-Nahal², Gina Cosentino³, Chiara Rizzo³, Maxime Breban⁴ and Simon Glatigny⁴, ¹Paris Saclay University / INSERM 1173, Montigny-le-Bretonneux, France, ²Rheumatology Division - Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France, ³INSERM 1173, Montigny-le-Bretonneux, France, ⁴1INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France
Background/Purpose: Spondylarthritis (SpA) is a group of chronic inflammatory disorders with osteoarticular and extraarticular symptoms, including colitis, highly associated with the human leukocyte antigen (HLA)…
Abstract Number: 2148 • ACR Convergence 2022
Analysis of Serum Proteomics Data Identifies Beta-Defensin 2 as a Predictive Biomarker of Clinical Response to IL-17 Blockade in Psoriatic Arthritis
Mathias Cardner¹, Danny Tuckwell², Anna Kostikova², Pascal Forrer³, Richard Siegel², Alain Marti³, Marc Vandemeulebroecke³ and Enrico Ferrero², ¹Novartis Global Drug Development and Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Novartis Institutes for BioMedical Research, Basel, Switzerland, ³Novartis Global Drug Development, Basel, Switzerland
Background/Purpose: Despite several effective targeted therapies, biomarkers that predict whether a patient with psoriatic arthritis (PsA) will respond to a particular treatment are currently lacking.Methods:…
Abstract Number: 0047 • ACR Convergence 2021
A Role for Neutrophils in Disease Onset and Severity of Spondyloarthritis
Holly Rosenzweig¹, Emily Vance², Rouhin sen³, Liron Caplan⁴ and Ruth Napier¹, ¹Oregon Health & Science University, Portland, OR, ²VA Portland Health Care System, Portland, OR, ³Colorado University Anschutz Medical Campus, Denver, CO, ⁴Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Spondyloarthritis (SpA) is a group of inflammatory diseases that includes axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). AxSpA patients have irregular neutrophil responses, as…
Abstract Number: 0050 • ACR Convergence 2021
Integrative Analysis of mRNAs to Identify Sex Differences in Th-17 Mediated Inflammation in Ankylosing Spondylitis
Maricela Haghiac¹, Maya Breitman², Ricky Chan³, Ahmad Khalil³ and Marina Magrey⁴, ¹Metrohealth Medical center, Cleveland, OH, ²MetroHealth Medical Center,Case Western Reserve University School of Medicine, Cleveland, OH, ³Case Western Reserve University, Cleveland, OH, ⁴Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH
Background/Purpose: Gender has been shown to impact disease expression in ankylosing spondylitis. Men with AS are more likely to develop radiographic joint damage, while women…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].